Lazard Capital Upgrades Meridian Biosciences (VIVO) to Buy, $36 Price Target
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $4.59 +8.77%
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Lazard Capital upgraded shares of Meridian Biosciences (NASDAQ: VIVO) to a Buy rating from Neutral. The firm also changed its price target to $36.
For more ratings news on Meridian Biosciences click here and for the rating history of Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $24.73 yesterday.
For more ratings news on Meridian Biosciences click here and for the rating history of Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $24.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
- JPMorgan Upgrades KCE Electronics PCL (KCE:TB) to Overweight
- Northcoast Upgrades CAVA Group Inc (CAVA) to Neutral
Create E-mail Alert Related Categories
UpgradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
